行动呼吁:英国和爱尔兰高血压协会关于血压治疗阈值和目标的立场声明。

IF 3.4 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Luca Faconti, Nayanatara Tantirige, Neil R. Poulter, Jacob George, Vikas Kapil, Ajay Gupta, Pauline A. Swift, Anthony Heagerty, Eduard Shantsila, Sarah Partridge, Ian B. Wilkinson
{"title":"行动呼吁:英国和爱尔兰高血压协会关于血压治疗阈值和目标的立场声明。","authors":"Luca Faconti, Nayanatara Tantirige, Neil R. Poulter, Jacob George, Vikas Kapil, Ajay Gupta, Pauline A. Swift, Anthony Heagerty, Eduard Shantsila, Sarah Partridge, Ian B. Wilkinson","doi":"10.1038/s41371-025-01055-z","DOIUrl":null,"url":null,"abstract":"In this position statement the British and Irish Hypertension Society (BIHS) present a review of the current evidence for blood pressure (BP) treatment thresholds and targets. The BIHS recommend initiating pharmacological antihypertensive therapy, irrespective of cardiovascular disease risk, following a confirmed diagnosis of hypertension (sustained out-of-office BP ≥ 135/85 mmHg despite diet and lifestyle advice). The BIHS recommend an on-treatment BP target < 130/80 mmHg or as low as reasonably achievable without causing unacceptable side-effects, within 6-months of initiating treatment, for all adults. Possible subgroups to whom this may not apply are those who are frail and/or have limited life expectancy where higher targets may be appropriate based on clinical judgement and the individuals’ tolerance to treatment. The BIHS believe that this simple 2-step approach will facilitate practitioners deliver evidence-based best practice, discourage therapeutic inertia around BP lowering and improve heath outcomes for all adults living with high BP.","PeriodicalId":16070,"journal":{"name":"Journal of Human Hypertension","volume":"39 8","pages":"537-540"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41371-025-01055-z.pdf","citationCount":"0","resultStr":"{\"title\":\"Call to action: British and Irish hypertension society position statement on blood pressure treatment thresholds and targets\",\"authors\":\"Luca Faconti, Nayanatara Tantirige, Neil R. Poulter, Jacob George, Vikas Kapil, Ajay Gupta, Pauline A. Swift, Anthony Heagerty, Eduard Shantsila, Sarah Partridge, Ian B. Wilkinson\",\"doi\":\"10.1038/s41371-025-01055-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this position statement the British and Irish Hypertension Society (BIHS) present a review of the current evidence for blood pressure (BP) treatment thresholds and targets. The BIHS recommend initiating pharmacological antihypertensive therapy, irrespective of cardiovascular disease risk, following a confirmed diagnosis of hypertension (sustained out-of-office BP ≥ 135/85 mmHg despite diet and lifestyle advice). The BIHS recommend an on-treatment BP target < 130/80 mmHg or as low as reasonably achievable without causing unacceptable side-effects, within 6-months of initiating treatment, for all adults. Possible subgroups to whom this may not apply are those who are frail and/or have limited life expectancy where higher targets may be appropriate based on clinical judgement and the individuals’ tolerance to treatment. The BIHS believe that this simple 2-step approach will facilitate practitioners deliver evidence-based best practice, discourage therapeutic inertia around BP lowering and improve heath outcomes for all adults living with high BP.\",\"PeriodicalId\":16070,\"journal\":{\"name\":\"Journal of Human Hypertension\",\"volume\":\"39 8\",\"pages\":\"537-540\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.comhttps://www.nature.com/articles/s41371-025-01055-z.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Human Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41371-025-01055-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Hypertension","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41371-025-01055-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

在这一立场声明中,英国和爱尔兰高血压协会(BIHS)提出了对当前血压(BP)治疗阈值和目标的证据的回顾。BIHS建议,在确诊高血压(尽管有饮食和生活方式建议,但门诊血压持续≥135/85 mmHg)后,无论心血管疾病风险如何,均应开始药物降压治疗。BIHS建议在开始治疗的6个月内,所有成年人的治疗期血压目标< 130/80 mmHg或在不产生不可接受的副作用的情况下尽可能低。可能不适用于身体虚弱和/或预期寿命有限的人群,根据临床判断和个人对治疗的耐受性,更高的目标可能是合适的。BIHS认为,这种简单的两步方法将促进从业者提供基于证据的最佳实践,阻止降低血压的治疗惰性,并改善所有高血压成人的健康结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Call to action: British and Irish hypertension society position statement on blood pressure treatment thresholds and targets

Call to action: British and Irish hypertension society position statement on blood pressure treatment thresholds and targets
In this position statement the British and Irish Hypertension Society (BIHS) present a review of the current evidence for blood pressure (BP) treatment thresholds and targets. The BIHS recommend initiating pharmacological antihypertensive therapy, irrespective of cardiovascular disease risk, following a confirmed diagnosis of hypertension (sustained out-of-office BP ≥ 135/85 mmHg despite diet and lifestyle advice). The BIHS recommend an on-treatment BP target < 130/80 mmHg or as low as reasonably achievable without causing unacceptable side-effects, within 6-months of initiating treatment, for all adults. Possible subgroups to whom this may not apply are those who are frail and/or have limited life expectancy where higher targets may be appropriate based on clinical judgement and the individuals’ tolerance to treatment. The BIHS believe that this simple 2-step approach will facilitate practitioners deliver evidence-based best practice, discourage therapeutic inertia around BP lowering and improve heath outcomes for all adults living with high BP.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Human Hypertension
Journal of Human Hypertension 医学-外周血管病
CiteScore
5.20
自引率
3.70%
发文量
126
审稿时长
6-12 weeks
期刊介绍: Journal of Human Hypertension is published monthly and is of interest to health care professionals who deal with hypertension (specialists, internists, primary care physicians) and public health workers. We believe that our patients benefit from robust scientific data that are based on well conducted clinical trials. We also believe that basic sciences are the foundations on which we build our knowledge of clinical conditions and their management. Towards this end, although we are primarily a clinical based journal, we also welcome suitable basic sciences studies that promote our understanding of human hypertension. The journal aims to perform the dual role of increasing knowledge in the field of high blood pressure as well as improving the standard of care of patients. The editors will consider for publication all suitable papers dealing directly or indirectly with clinical aspects of hypertension, including but not limited to epidemiology, pathophysiology, therapeutics and basic sciences involving human subjects or tissues. We also consider papers from all specialties such as ophthalmology, cardiology, nephrology, obstetrics and stroke medicine that deal with the various aspects of hypertension and its complications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信